Several therapeutic agents, such as tyrosine kinase and mTOR inhibitors as well as immunotherapeutics (sunitinib or sorafenib), have demonstrated significant improvements regarding response rates, cancer-specific progression-free survival rates, and overall survival rates of advanced RCC patients. The gene discussed is MTOR; the disease is renal cell carcinoma.